The Center will support the R and D and manufacturing of Sonoma Bio's pipeline of gene-modified Treg therapies for autoimmune and inflammatory diseases at scale.
This R and D and Manufacturing Center will include the development and use of technologies and capabilities from cell selection and genetic modification to intelligent manufacturing automation and information technology systems.
The integration of this infrastructure and scientific expertise will enable Sonoma Bio to move efficiently from molecular target identification to in-house full-scale production for multiple product candidates and indications in Phase 2 clinical trials and beyond.
The Center will be located on the Seattle waterfront at 501 Elliott Avenue West, a property owned by Office Properties Income Trust and being redeveloped by The RMR Group into Unison Elliott Bay.
Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system.
Sonoma Biotherapeutics is based in South San Francisco and Seattle.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
AstraZeneca increases dividend by 7%
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
Wolters Kluwer enhances Clinical GenAI leadership with AI Labs powered by UpToDate
Amgen announces share dividend for Q2 2024
Virbac expands presence in Japan with Sasaeah acquisition
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva